If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk is working on a new obesity drug that could help patients ... Semaglutide, the GLP-1 drug that Novo sells under ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...